These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 26589654)

  • 1. Costs of non-small cell lung cancer in the Netherlands.
    van der Linden N; Bongers ML; Coupé VM; Smit EF; Groen HJ; Welling A; Schramel FM; Uyl-de Groot CA
    Lung Cancer; 2016 Jan; 91():79-88. PubMed ID: 26589654
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Direct costs associated with the disease management of patients with unresectable advanced non-small-cell lung cancer in The Netherlands.
    Pompen M; Gok M; Novák A; van Wuijtswinkel R; Biesma B; Schramel F; Stigt J; Smit H; Postmus P
    Lung Cancer; 2009 Apr; 64(1):110-6. PubMed ID: 18805601
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Changing costs of metastatic non small cell lung cancer in the Netherlands.
    Keusters WR; de Weger VA; Hövels A; Schellens JHM; Frederix GWJ
    Lung Cancer; 2017 Dec; 114():56-61. PubMed ID: 29173766
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Estimating the cost of lung cancer diagnosis and treatment in Canada: the POHEM model.
    Evans WK; Will BP; Berthelot JM; Wolfson MC
    Can J Oncol; 1995 Dec; 5(4):408-19. PubMed ID: 8770457
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Real-world treatment patterns and costs in a US Medicare population with metastatic squamous non-small cell lung cancer.
    Davis KL; Goyal RK; Able SL; Brown J; Li L; Kaye JA
    Lung Cancer; 2015 Feb; 87(2):176-85. PubMed ID: 25532680
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Economic burden of resected (stage IB-IIIA) non-small cell lung cancer in France, Germany and the United Kingdom: A retrospective observational study (LuCaBIS).
    Andreas S; Chouaid C; Danson S; Siakpere O; Benjamin L; Ehness R; Dramard-Goasdoue MH; Barth J; Hoffmann H; Potter V; Barlesi F; Chirila C; Hollis K; Sweeney C; Price M; Wolowacz S; Kaye JA; Kontoudis I
    Lung Cancer; 2018 Oct; 124():298-309. PubMed ID: 29961557
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A population-based study of the resource utilization and costs of managing resectable non-small cell lung cancer.
    Mahar AL; Coburn NG; Johnson AP
    Lung Cancer; 2014 Nov; 86(2):281-7. PubMed ID: 25267166
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment cost of non-small cell lung cancer in three European countries: comparisons across France, Germany, and England using administrative databases.
    McGuire A; Martin M; Lenz C; Sollano JA
    J Med Econ; 2015; 18(7):525-32. PubMed ID: 25802950
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An economic analysis of sublobar resection versus thermal ablation for early-stage non-small-cell lung cancer.
    Kwan SW; Mortell KE; Hippe DS; Brunner MC
    J Vasc Interv Radiol; 2014 Oct; 25(10):1558-64; quiz 1565. PubMed ID: 25130308
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Management of febrile neutropenia--a German prospective hospital cost analysis in lymphoproliferative disorders, non-small cell lung cancer, and primary breast cancer.
    Ihbe-Heffinger A; Paessens BJ; von Schilling C; Shlaen M; Gottschalk N; Berger K; Bernard R; Kiechle M; Peschel C; Jacobs VR
    Onkologie; 2011; 34(5):241-6. PubMed ID: 21577029
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Epidemiology and treatment costs of bone metastases from lung cancer: a French prospective, observational, multicenter study (GFPC 0601).
    Decroisette C; Monnet I; Berard H; Quere G; Le Caer H; Bota S; Audigier-Valette C; Geriniere L; Vernejoux JM; Chouaid C;
    J Thorac Oncol; 2011 Mar; 6(3):576-82. PubMed ID: 21270669
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Brain metastases in patients with ALK+ non-small cell lung cancer: clinical symptoms, treatment patterns and economic burden.
    Guérin A; Sasane M; Zhang J; Culver KW; Dea K; Nitulescu R; Wu EQ
    J Med Econ; 2015 Apr; 18(4):312-22. PubMed ID: 25565443
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Diagnostic and therapeutic approaches to lung cancer in Canada and their costs.
    Evans WK; Will BP; Berthelot JM; Wolfson MC
    Br J Cancer; 1995 Nov; 72(5):1270-7. PubMed ID: 7577481
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Health care resource utilization and costs associated with advanced or metastatic nonsmall cell lung cancer in the United States.
    Zhang X; Beachler DC; Masters E; Liu F; Yang M; Dinh J; Jamal-Allial A; Kolitsopoulos F; Lamy FX
    J Manag Care Spec Pharm; 2022 Feb; 28(2):255-265. PubMed ID: 34854733
    [No Abstract]   [Full Text] [Related]  

  • 15. Metastatic non-small cell lung cancer: costs associated with disease progression.
    Fox KM; Brooks JM; Kim J
    Am J Manag Care; 2008 Sep; 14(9):565-71. PubMed ID: 18778171
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Economic burden of patients affected by non-small cell lung cancer (NSCLC): the LIFE study.
    Migliorino MR; Santo A; Romano G; Cortinovis D; Galetta D; Alabiso O; Cartenì G; Vari S; Fasola G; Pazzola A; Giuffrida D; Zaniboni A; Caprioli A; Longo F; Acciai V; de Marinis F
    J Cancer Res Clin Oncol; 2017 May; 143(5):783-791. PubMed ID: 28215027
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Event-free survival as a predictor of overall survival and recurrence burden of patients with non-small cell lung cancer receiving neoadjuvant therapy.
    Donington J; Hu X; Zhang S; Song Y; Arunachalam A; Chirovsky D; Gao C; Lerner A; Jiang A; Signorovitch J; Samkari A
    J Thorac Cardiovasc Surg; 2024 Oct; 168(4):1261-1269.e1. PubMed ID: 38092284
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-of-illness study for non-small-cell lung cancer using real-world data.
    Seung SJ; Hurry M; Hassan S; Walton RN; Evans WK
    Curr Oncol; 2019 Apr; 26(2):102-107. PubMed ID: 31043811
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluating Expected Costs and Benefits of Granting Access to New Treatments on the Basis of Progression-Free Survival in Non-Small-Cell Lung Cancer.
    Lakdawalla DN; Chou JW; Linthicum MT; MacEwan JP; Zhang J; Goldman DP
    JAMA Oncol; 2015 May; 1(2):196-202. PubMed ID: 26181023
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Estimation of lung cancer diagnosis and treatment costs based on a patient-level analysis in Catalonia (Spain).
    Corral J; Espinàs JA; Cots F; Pareja L; Solà J; Font R; Borràs JM
    BMC Health Serv Res; 2015 Feb; 15():70. PubMed ID: 25889153
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.